Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Trial Details

NCT ID

NCT06767813

Phase

PHASE2

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• TQB2868 injection
• Gemcitabine injection
• Albumin paclitaxel injection
• Anlotinib capsules

Locations (sample)

• Zhengzhou, Henan, China|34.75778,113.64861
• Zhengzhou, Henan, China|34.75778,113.64861
• Nanjing, Jiangsu, China|32.06167,118.77778
• Nanjing, Jiangsu, China|32.06167,118.77778
• Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

• Subjects must voluntarily participate in the study and sign the informed consent form.
• Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
• Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
• Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.